Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group.

N Engl J Med. 2002 Jan 24;346(4):225-34. Erratum in: N Engl J Med. 2007 Feb 15;356(7):760.

2.

Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK.

Cochrane Database Syst Rev. 2014 Feb 24;(2):CD004707. doi: 10.1002/14651858.CD004707.pub3. Review.

PMID:
24563222
3.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
4.

Voriconazole versus amphotericin B in cancer patients with neutropenia.

Jørgensen KJ, Gøtzsche PC, Johansen HK.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004707. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD004707.

PMID:
16437492
5.

Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.

Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH.

Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006343. doi: 10.1002/14651858.CD006343.pub2. Review.

PMID:
20166083
6.

[Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].

Badia X, Roset M, Carreras E, Ausin I, Herrera L.

Med Clin (Barc). 2004 May 1;122(16):610-6. Review. Spanish.

PMID:
15142508
7.

Modern antifungal therapy for neutropenic fever.

Corey M.

Curr Hematol Malig Rep. 2006 Jun;1(2):95-100. doi: 10.1007/s11899-006-0029-0. Review.

PMID:
20425338
8.

The role of voriconazole in the treatment of central nervous system blastomycosis.

Ta M, Flowers SA, Rogers PD.

Ann Pharmacother. 2009 Oct;43(10):1696-700. doi: 10.1345/aph.1M010. Epub 2009 Sep 1. Review.

PMID:
19724015
9.

Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?

Pagano L, Valentini CG, Fianchi L, Caira M.

J Chemother. 2011 Feb;23(1):5-8. Review.

PMID:
21482486
10.

Voriconazole: a new triazole antifungal agent.

Pearson MM, Rogers PD, Cleary JD, Chapman SW.

Ann Pharmacother. 2003 Mar;37(3):420-32. Review.

PMID:
12639175
11.

Use of newer antifungal therapies in clinical practice: what do the data tell us?

Perfect JR.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 7):15-23. Review.

12.

Treating disseminated fusariosis: amphotericin B, voriconazole or both?

Ho DY, Lee JD, Rosso F, Montoya JG.

Mycoses. 2007 May;50(3):227-31. Review.

PMID:
17472622
13.

An update on the use of antifungal agents.

Martinez R.

J Bras Pneumol. 2006 Sep-Oct;32(5):449-60. Review. English, Portuguese.

14.

Voriconazole.

Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB.

Clin Ther. 2003 May;25(5):1321-81. Review.

PMID:
12867215
15.

Voriconazole : a review of its use in the management of invasive fungal infections.

Scott LJ, Simpson D.

Drugs. 2007;67(2):269-98. Review.

PMID:
17284090
16.

[Current indications for voriconazole in onco-hematological patients].

Jarque I, Sanz MA.

Rev Iberoam Micol. 2007 Sep 30;24(3):213-6. Review. Spanish.

17.

Voriconazole: in the treatment of invasive aspergillosis.

Muijsers RB, Goa KL, Scott LJ.

Drugs. 2002;62(18):2655-64; discussion 2665-6. Review.

PMID:
12466006
18.

New antifungal drugs and the pediatric cancer patient: current status of clinical development.

Groll AH, Lehrnbecher T.

Klin Padiatr. 2005 May-Jun;217(3):158-68. Review.

PMID:
15858708
19.

Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.

Klastersky J, Paesmans M.

Support Care Cancer. 2007 Feb;15(2):137-41. Epub 2006 Sep 12. Review.

PMID:
16967301
20.

Clinical hepatotoxicity associated with antifungal agents.

Kyriakidis I, Tragiannidis A, Munchen S, Groll AH.

Expert Opin Drug Saf. 2017 Feb;16(2):149-165. doi: 10.1080/14740338.2017.1270264. Epub 2016 Dec 16. Review.

PMID:
27927037

Supplemental Content

Support Center